Vanguard Group Inc Intellia Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 10,852,169 shares of NTLA stock, worth $118 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,852,169
Previous 10,752,031
0.93%
Holding current value
$118 Million
Previous $76.4 Million
33.16%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding NTLA
# of Institutions
333Shares Held
96.5MCall Options Held
1.76MPut Options Held
1.05M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$141 Million1.01% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$104 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.12MShares$44.7 Million0.0% of portfolio
-
State Street Corp Boston, MA4.04MShares$43.9 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.68MShares$29.1 Million0.25% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $825M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...